Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity
Cory Allen(Mayo Clinic), Evanthia Galanis(Mayo Clinic in Arizona), Sompong Vongpunsawad(Mayo Clinic), Joon H. Uhm(Mayo Clinic), Stephen J. Russell(University of Minnesota Rochester), James Krempski(University of North Carolina at Chapel Hill), Caterina Giannini(Mayo Clinic), Takafumi Nakamura(Tottori University), Kah-Whye Peng(University of Minnesota Rochester), Roberto Cattaneo(Mayo Clinic in Arizona), C. David James(Mayo Clinic in Arizona), Mark A. Schroeder(MACOM (United States)), Jenny M. Goble(Mayo Clinic)
Cited by 106
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
|BMC Medicine|2008|948
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
|Journal of Clinical Oncology|2005|695